Estimation of treatment effect under non-proportional hazards and conditionally independent censoring

被引:17
作者
Boyd, Adam P. [2 ]
Kittelson, John M. [1 ]
Gillen, Daniel L. [3 ]
机构
[1] Univ Colorado Denver, Dept Biostat & Informat, Aurora, CO 80045 USA
[2] Novartis Pharma AG, CH-4002 Basel, Switzerland
[3] Univ Calif Irvine, Dept Stat, Irvine, CA 92697 USA
关键词
multiplicative hazards model; partial likelihood; time-varying effects; weighted estimator; REGRESSION-MODELS; CLINICAL-TRIALS; INFERENCE; TESTS; BIAS;
D O I
10.1002/sim.5440
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
In clinical trials with time-to-event outcomes, it is common to estimate the marginal hazard ratio from the proportional hazards model, even when the proportional hazards assumption is not valid. This is unavoidable from the perspective that the estimator must be specified a priori if probability statements about treatment effect estimates are desired. Marginal hazard ratio estimates under non-proportional hazards are still useful, as they can be considered to be average treatment effect estimates over the support of the data. However, as many have shown, under non-proportional hazard, the usual unweighted marginal hazard ratio estimate is a function of the censoring distribution, which is not normally considered to be scientifically relevant when describing the treatment effect. In addition, in many practical settings, the censoring distribution is only conditionally independent (e.g., differing across treatment arms), which further complicates the interpretation. In this paper, we investigate an estimator of the hazard ratio that removes the influence of censoring and propose a consistent robust variance estimator. We compare the coverage probability of the estimator to both the usual Cox model estimator and an estimator proposed by Xu and O'Quigley (2000) when censoring is independent of the covariate. The new estimator should be used for inference that does not depend on the censoring distribution. It is particularly relevant to adaptive clinical trials where, by design, censoring distributions differ across treatment arms. Copyright (C) 2012 John Wiley & Sons, Ltd.
引用
收藏
页码:3504 / 3515
页数:12
相关论文
共 22 条